Biotech News

CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026

CorMedix Inc. (CRMD)CorMedix Inc.Earnings

CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call at 8:30 a.m. Eastern Standard Time.

Related news

CorMedix Inc.

Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care. DefenCath DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult...

Recent company news

Stock data

Close
5.08 USD
Market cap
640.95M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States